{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:53:46Z","timestamp":1791237226927,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cpcardiol.2022.101386","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T19:32:25Z","timestamp":1661974345000},"page":"101386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection"],"prefix":"10.1016","volume":"47","author":[{"given":"Dominic","family":"Parfianowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swara","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa N.","family":"Maitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrija","family":"Hajra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakumar","family":"Sreenivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-2119","authenticated-orcid":false,"given":"Rahul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101386_bib0001","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0002","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1204598","article-title":"Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology","volume":"2018","author":"Cannavo","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.14797\/mdcj-11-4-235","article-title":"Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure","volume":"11","author":"Sica","year":"2015","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0004","doi-asserted-by":"crossref","first-page":"e006540","DOI":"10.1161\/JAHA.117.006540","article-title":"Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease","volume":"6","author":"Cooper","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0005","article-title":"Firibastat: a novel brain aminopeptidase inhibitor - a new era of antihypertensive therapy","author":"Gupta","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0007","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0008","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11906-016-0649-2","article-title":"Finerenone: a new mineralocorticoid receptor antagonist without hyperkalemia: an opportunity in patients with CKD?","volume":"18","author":"Haller","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0012","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.85.7.643","article-title":"The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?","volume":"85","author":"Dostal","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0013","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","article-title":"Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness","volume":"72","author":"Jia","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0014","doi-asserted-by":"crossref","first-page":"e003588","DOI":"10.1161\/CIRCHEARTFAILURE.116.003588","article-title":"Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: a meta-analysis of published study data","volume":"10","author":"Beldhuis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0167-0115(00)00178-6","article-title":"The multiple actions of angiotensin II in atherosclerosis","volume":"93","author":"Schmidt-Ott","year":"2000","journal-title":"Regul Pept"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0016","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.HYP.25.2.219","article-title":"Cellular distribution of angiotensin-converting enzyme after myocardial infarction","volume":"25","author":"Falkenhahn","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0017","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1161\/01.CIR.90.4.2056","article-title":"Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection","volume":"90","author":"Lonn","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0018","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/01.RES.73.3.413","article-title":"Molecular characterization of angiotensin II\u2013induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype","volume":"73","author":"Sadoshima","year":"1993","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0019","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI117322","article-title":"Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction","volume":"94","author":"Studer","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00424-008-0616-0","article-title":"Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?","volume":"458","author":"Gekle","year":"2009","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0021","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0022","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","article-title":"Mineralocorticoid receptor antagonists: a comprehensive review of finerenone","volume":"22","author":"Rico-Mesa","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0023","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0024","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0025","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijbiomac.2021.10.165","article-title":"Mechanistic insights into the role of serum-glucocorticoid kinase 1 in diabetic nephropathy: A systematic review","volume":"193","author":"Noor","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.ctdb.2016.11.006","article-title":"SGK1: the dark side of PI3K signaling","volume":"123","author":"Di Cristofano","year":"2017","journal-title":"Curr Top Dev Biol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0027","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0028","first-page":"390","article-title":"Tenascin-x facilitates myocardial fibrosis and cardiac remodeling through transforming growth factor-beta1 and peroxisome proliferator-activated receptor gamma in alcoholic cardiomyopathy","volume":"124","author":"Jing","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0029","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/HYPERTENSIONAHA.115.06004","article-title":"Tenascin-C may accelerate cardiac fibrosis by activating macrophages via the integrin alphaVbeta3\/nuclear factor-kappaB\/interleukin-6 axis","volume":"66","author":"Shimojo","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0030","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0031","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0032","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonzalez-Blazquez","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0033","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0034","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0035","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","article-title":"Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo","volume":"43","author":"Heinig","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0036","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s13318-020-00610-y","article-title":"Results from drug-drug interaction studies in vitro and in vivo investigating the effect of finerenone on the pharmacokinetics of comedications","volume":"45","author":"Heinig","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0037","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (bay 94-8862) in individuals with mild or moderate hepatic impairment","volume":"44","author":"Heinig","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0038","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0039","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13318-022-00770-z","article-title":"Results from phase i studies investigating the dose linearity of finerenone tablets and the influence of food or ph-modifying comedications on its pharmacokinetics in healthy male volunteers","volume":"47","author":"Heinig","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0041","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0042","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0043","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (bay 94-8862) in individuals with renal impairment","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0044","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0045","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/ndt\/gfy065","article-title":"Mineralocorticoid receptor antagonists in kidney transplantation: time to consider?","volume":"33","author":"Girerd","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0046","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/196418","article-title":"Could mineralocorticoids play a role in the pathophysiology of open angle glaucoma?","volume":"2012","author":"May","year":"2012","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0047","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0048","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.21037\/apm-21-763","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis","volume":"10","author":"Fu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0049","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0050","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0051","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0052","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0053","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0054","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17512433.2022.2051480","article-title":"Growing role of SGLT2i in heart failure: evidence from clinical trials","volume":"15","author":"Varadhan","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0056","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and Type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.cpcardiol.2022.101386_bib0057","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:00:12Z","timestamp":1758938412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622002833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0146280622002833"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101386","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101386"}}